XTALPi and CK Life Sciences Collaborate on AI-Driven miRNA-Based Molecular Diagnostic Model for Cancer Prognosis

ShenzhenNovember 6, 2023PR Newswire -- Today, XtalPi, an AI and robotics-driven company empowering life science research, announced a new R&D collaboration with CK Life Sciences. The two companies will combine artificial intelligence (AI) algorithms with desensitized clinical diagnostic and biomarker data from cancer patients and healthy individuals to jointly explore and develop miRNA-based molecular diagnostic models for cancer prognosis risk prediction. Leveraging AI and machine learning, this collaboration aims to create more advanced and intelligent solutions for multidimensional biological data modeling, tumor biomarker discovery, and postoperative recurrence risk prediction for patients.

In recent years, with the increasing integration of modern experimental technologies into clinical research, the industry has accumulated a wealth of data from various dimensions such as omics, cells, and tissues. The combination of this data with the rapidly advancing artificial intelligence technology is expected to provide more tools and bring new opportunities and possibilities to clinical disease research and drug discovery through more efficient models. Taking early diagnosis as an example, currently, a large amount of medical resources are invested in the treatment phase after disease confirmation. In recent years, with the continuous decline in high-throughput sequencing costs, the scale of mRNA and miRNA data from real-world sources has been increasing, becoming a major trend in the industry. Effectively mining the potential value in these complex datasets through AI algorithms can lead to the discovery of new disease biomarkers, train efficient models for molecular diagnostics, thereby effectively predicting patients' postoperative prognosis and recurrence risks, and reducing the waste of medical resources. This has therefore drawn significant attention from the healthcare and biopharmaceutical industries.

XtalPi, as an R&D platform that combines AI with robotics, has been deeply engaged in the development and application of cutting-edge algorithms in the field of life sciences for many years. It possesses a unique algorithm platform and technical advantages, accumulating extensive technologies and experience in biological sequence modeling such as proteins and genes. CK Life Sciences Int'l., (Holdings) Inc. has long been actively committed to the research and development of cancer vaccines and diagnostic technologies, amassing abundant medical diagnostic and biomarker data through clinical studies. By fully leveraging its expertise and strategic collaborations in key areas, CK Life Sciences is dedicated to advancing innovations in cancer treatment, striving to continuously improve patient outcomes through pioneering tumor diagnostic research.

At the end of 2022, XtalPi and CK Life Sciences Int'l., (Holdings) Inc. signed a collaboration agreement to jointly develop an AI tumor vaccine research platform, exploring innovative approaches to enhance the discovery and design capabilities for tumor vaccines. In this collaboration, the two companies will focus on a specific type of cancer as a starting point. By integrating CK Life Sciences' extensive desensitized multi-dimensional clinical molecular diagnostic data with machine learning algorithms, they aim to achieve breakthroughs in modeling capabilities within the miRNA omics data field. The goal is to develop highly accurate clinical tumor diagnostic models that can help doctors predict the risk of cancer recurrence in patients after surgery at an early stage, customize targeted postoperative treatment plans, and improve the survival rate and quality of life for cancer patients. Additionally, the two companies hope to discover important biomarkers through this project, providing robust computational model support for clinical diagnosis, disease management, and new drug screening, while laying the technical foundation for future large-scale collaborations based on more complex data.

XtalPi looks forward to the future, where this model will be extended to the analysis of other omics data such as genomics, proteomics, and metabolomics, achieving the integration of multi-modal data including omics data and imaging data. This will enable more comprehensive and precise predictions in key application scenarios such as biomarker discovery for more diseases, clinical diagnosis and disease risk prediction, new drug discovery, and drug repurposing.

Lai Lipeng, Co-founder and Chief Innovation Officer of XtalPi

Dr. Lai Lipeng, Co-founder and Chief Innovation Officer of XtalPi, stated, "CK Life Sciences possesses a strong scientific team and has accumulated large-scale, high-quality clinical molecular diagnostic data, providing a valuable foundation for this collaboration. By leveraging XtalPi's capabilities in AI model construction and the experience gained from previous projects, as well as utilizing cutting-edge technologies like language models, we anticipate that the integration of AI and clinical data will demonstrate breakthrough value in this partnership, leading to enhanced clinical molecular diagnostic solutions. At the same time, we are both highly anticipating that through our cooperation, we will jointly explore an AI solution applicable to more diverse and complex data, supporting critical tasks such as biomarker discovery and clinical diagnosis more efficiently, ultimately benefiting more patients."

Du Jianming, Vice President and Chief Scientific Officer of CK Life Sciences Int'l., (Holdings) Inc.

Dr. Melvin Toh, Vice President and Scientific Director of CK Life Sciences, stated, "In cancer management, diagnostic and prognostic testing play a crucial role and are key components in refining cancer treatment. Early detection of cancer enables us to intervene promptly and initiate treatment in a timely manner. At the same time, by predicting and assessing patients at higher risk of recurrence and disease progression, it helps doctors tailor treatment strategies accordingly. We look forward to collaborating with the outstanding data scientists at XtalPi to jointly develop innovative molecular diagnostic solutions for cancer, thereby improving patient outcomes."

About XtalPi

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to fuel innovation. Founded in 2014 at the Massachusetts Institute of Technology (MIT) in the United States, it is committed to realizing digital and intelligent transformations in the life sciences and new materials fields. The company leverages cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robotics clusters to provide innovative technologies, services, and products for global industries including biomedicine, chemicals, new energy, and advanced materials.

About CK Life Sciences Int'l., (Holdings) Inc.

CK Life Sciences Int'l., (Holdings) Inc. (Stock Code: 0775) is listed on the Hong Kong Stock Exchange. With the mission of enhancing the quality of human life, CK Life Sciences engages in the research and development, manufacturing, commercialization, promotion, sales, and investment of products, covering projects and assets in three major areas: health, medical diagnostics, and agriculture-related businesses. CK Life Sciences is a member of the CK Hutchison Holdings group.